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Background: Due to the improvement in life expectancy in cystic fibrosis (CF), co-morbidities such as renal function impairment may be more
frequent.
Aim: To determine the prevalence of renal disease in children with CF and to identify associated risk factors.
Methods: A single-center retrospective study analyzing the genetic, clinical and therapeutic characteristics of 112 children. The estimated
glomerular filtration rate (GFR), microalbuminuria and lithiasic risk factors were assessed.
Results: The median calculated GFR (Schwartz) was 123, 161 and 155 ml/min/1.73 m2 in children aged 1, 6 and 15 years, respectively. The
cumulative dose of aminoglycosides was not correlated to GFR. Microalbuminuria was present in 22/38 patients. Hyperoxaluria was observed in
58/83 patients and was associated with a severe genotype, pancreas insufficiency and liver disease. Hypercalciuria, hyperuricuria and
hypocitraturia were identified in 16/87, 15/83 and 57/76 patients, respectively.
Conclusion: Renal impairment in CF has various presentations. There appears to be low levels of renal impairment in children with CF. However,
the risk of oxalocalcic urolithiasis is enhanced, and GFR may be underestimated by the Schwartz formula. Further studies using measured GFR
techniques are thus warranted.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Child; Nephrotoxicity; Kidney disease; Urolithiasis; Antibiotics1. Background
The life expectancy of patients with cystic fibrosis (CF) has
dramatically increased over the past decades [1], raising the
concern about the onset of new co-morbidities associated with
CF such as diabetes mellitus and renal impairment. In the
seventies, the average life expectancy in CF was approximately
14 years whereas in 2003 [2], more than 50% of the patients had☆ Part of the data reported here has been presented at the annual meeting of the
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and printed in abstract form (J Cyst Fibros 8: S111, 2009).
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doi:10.1016/j.jcf.2010.03.006reached the age of 25 years. The number of patients aged
40 years is also increasing, and the median survival of patients
born in 2000 is expected to be above 50 years [3].
Therefore, the risk for renal impairment in patients with CF
has become a reason for concern as indicated by a very recent
review [4]. Indeed, these patients are at higher risk of
developing urolithiasis and nephrocalcinosis. This has been
illustrated by studies revealing increased urinary excretion of
factors promoting lithogenesis (such as hyperoxaluria or
hypercalciuria) and decreased urinary excretion of inhibiting
factors such as citraturia [5–7]. Moreover, the use of
nephrotoxic drugs in the treatment of pulmonary disease, such
as antibiotics (in particular aminoglycosides) and non-steroidal
anti-inflammatory agents, may lead to renal injury [8–10]. With
improved life expectancy, the use of nephrotoxic drugs may
increase over time, exposing presently young patients to greaterd by Elsevier B.V. All rights reserved.
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and liver disease will also become more frequent in the next
years, leading to even more complex treatment strategies [11].
Therefore, the prevention of renal impairment has become a
crucial issue, in order to improve patient survival and quality of
life.
To complicate matters more, patients with end-stage
respiratory failure benefitting from lung transplantation have
an additional risk of renal impairment. Indeed, chronic renal
failure has been shown to be the most frequent non-infectious
medical complication after lung transplantation [12]. Bech et al.
also showed an early and important decrease in measured
glomerular filtration rate in transplanted patients [13]. In some
instances, further renal transplantation was required. In these
studies, the decrease in renal function after transplantation was
related to pre-existing renal impairment and the nephrotoxicity
of calcineurin inhibitors. It is thus important to preserve renal
function in patients with CF, from childhood to adult age, in
order to optimize the conditions of their survival and to achieve
the least minimal renal damage prior to transplantation.
Despite all of the above, there are limited data regarding
renal impairment in children with CF. We hypothesize that in
such a population, underlying renal disease might be more
frequent than previously believed.
The aim of the present study was thus to determine the
prevalence of various forms of renal disease in a population of
children with CF, and to identify associated risk factors.
2. Methods
2.1. Population
A single-center retrospective study was conducted at the
tertiary-care Paediatric Department of Bordeaux University
Hospital, France. This study focused on the patients followed at
the Paediatric Cystic Fibrosis Unit (Centre de Ressources et de
Compétences de la Mucoviscidose, CRCM) between 1998 and
2008.
Overall, the children were examined on a monthly basis in
the first year of life and every 3 months thereafter. A full
clinical, imaging and laboratory health assessment was
performed yearly.
Patients whose diagnosis was confirmed by molecular
biology (two identified mutations) and/or by two positive
sweat tests were included. Diagnosis was made prior to the age
of 18 years and all patients were still being followed at the
CRCM at the time of the study. Patients presenting with Cystic
Fibrosis Transmembrane Regulator (CFTR) disease other than
CF were excluded, as well as those who had settled down
elsewhere during the study period (incomplete data).
Patients' data were collected up to May 2008, using medical
files of the Paediatric CRCM of Bordeaux.
2.2. Data collection
The following data were recorded for each patient: date of
birth, gender, history of meconial ileus, date of diagnosis of CF,genotype, follow-up period, Body Mass Index at 2, 5, 10 and
15 years. In patients who had undergone neonatal screening, the
4th day of life was considered as the date of diagnosis of CF.
Mutation screening for the CFTR gene was performed either
by PCR and reverse dot-blot hybridization or by PCR-
sequencing. Mutations were classified into three categories,
according to the present knowledge regarding their expected
phenotypic expression: severe, mild or unknown [14].
2.3. Definitions
Pancreatic insufficiency was defined as stool pancreatic
elastase rate below 200 μg/g, as assessed by an ELISA test
using monoclonal antibodies [15].
Liver disease was defined by the presence of at least one of
the following features: clinically observed hepatomegaly for at
least 6 months, liver enzyme levels above the upper limit of
normal over a time span of at least 6 months (laboratory norms:
ASAT 10 to 70 IU/ml, ALAT 5 to 40 IU/ml) and abnormal
ultrasonography (heterogeneous or nodular liver, hepatomegaly
and/or signs of portal hypertension) [16,17].
The diagnosis of diabetes mellitus was confirmed by an oral
glucose tolerance test. Patients partially intolerant to carbohy-
drates were not classified as diabetic.
Chronic colonization by Pseudomonas aeruginosa was
defined by at least 3 positive sputum tests for this bacteria
and no negative test within the 6 months preceding the study.
Patients with a history of primary infection already efficiently
treated or running for less than 6 months were not noted for this
feature.
The cumulative number of days of intravenous (IV)
antibiotherapy (tobramycin, gentamycin, amikacin, netilmycin,
vancomycin, teicoplanin and ciprofloxacin) and the cumulative
number of months of inhaled antibiotherapy (colistin and
tobramycin) received by the patients were also reported. IV
aminoglycosides were always administered on a once-daily
basis.
2.4. Renal investigations
GFR was recorded at 1, 3, 6, 9, 12 and 15 years using the
Schwartz formula (GFR(schw)) or the UV/P formula (GFR(uv/
p)). The Schwartz formula used was: [k×height (cm)] /plasma
creatinine (μmol/l), with k=40 before 2 years of age, k=49
from 2 to 13 years of age, and k=62 for males (49 for females)
after 13 years of age [18]. The UV/P formula is a calculated
GFR method defined as [(urinary creatinine×urinary 24-hour
volume) /plasma creatinine]× (1.73/body surface area). The
blood and urine samples used for the determination of GFR
were essentially obtained during hospitalization. GFR impair-
ment was defined as a filtration rate below 90 ml/min/1.73 m2.
The urinary albumin/creatinine ratio, performed in fresh
urine samples to assess microalbuminuria, was considered to be
abnormal according to the European Society for Paediatric
Nephrology definition (N5 mg/mmol if age is b2 years, N2 mg/
mmol if age is ≥2 years) [19]. Assays were performed using a
Modular auto-analyzer (Roche/Hitachi) by the ELISA method
Table 1
Patient characteristics.
Variables Total (n=112)
Sex (boys/girls) 59/53
Age at diagnosis (months) 4.3 [0.3–57.8]
Age at the end of study (years) 8.3 [3.9–13.0]
Follow-up period
Before CRCM 49/112 (44)
CRCM 27/112 (24)
Neonatal screening 36/112 (32)
Follow-up (years) 6 [3.0–10.4]
Body Mass Index (kg/m2)
2 years 15.5 [14.9–16.6]
5 years 15.2 [14.5–16.3]
10 years 16.2 [14.8–18.0]
15 years 19.0 [16.7–20.8]
Genotype
p.508.del/p.508.del 51/112 (46)
p.508.del/other 44/112 (39)
Other/other 16/112 (14)
p.508.del/unknown 1/112 (1)
Genotypic severity
Severe/severe 93/112 (83)
Severe/mild 17/112 (15)
Mild/mild 1/112 (1)
Severe/unknown 1/112 (1)
Meconial ileus 13/112 (12)
Pancreatic insufficiency (n=97) 78/97 (80)
Liver disease 29/112 (26)
Diabetes mellitus 5/112 (4)
Colonization with Pseudomonas aeruginosa 23/112 (21)
Intravenous antibiotics 57/112 (51)
Inhaled antibiotics 70/112 (63)
CRCM: Centre de Ressources et de Compétences de la Mucoviscidose.
n (%) or median [IQR].
Fig. 1. Calculated GFR according to Schwartz formula. Results are median
[IQR] ml/min/1.73 m2, according to age (1 year n=44; 3 years n=54; 6 years
n=46; 9 years n=34; 12 years n=28; 15 years n=16). Small circles correspond
to the range.
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creatinine.
Kidney size and cortico-medullar differentiation were
assessed by ultrasonography in the Department of Radiology
of Bordeaux Hospital. Lithiasic risk factors were estimated by
the oxalate/creatinine, calcium/creatinine, uric acid/creatinine
and citrate/creatinine ratios, during a cristalluria test (single
urine sample) or a 24-hour urine sample. Hypocitraturia was
defined by a citrate/creatinine ratio of b0.3 mmol/mmol.
Hyperoxaluria, hypercalciuria and hyperuricuria were defined
according to the patient's age as in previously reported data
[19,20]. Urinary oxalate and citrate were measured by High
Performing Liquid Chromatography and “step gradient”
technique. Urinary calcium and uric acid were measured by
the ELISA method and enzymatic method respectively, using
a Modular auto-analyzer. The presence of urolithiasis and
nephrocalcinosis was assessed by ultrasonography. Patients
were considered at risk of urolithiasis if at least one risk factor
was found.
2.5. Statistical analysis
Statistical analysis was performed using NCSS® software
(Kaysville, Utah, USA). Data are presented as percentages for
categorical variables and mean±SD or median and interquar-
tile range for continuous variables. Pearson or Spearman
correlations test was used. In order to examine the association
between some exposure variables (age, genotype, liver disease,
pancreatic insufficiency, diabetes, chronic colonization by
P. aeruginosa and cumulative number of days of antibiotics)
and the dependent variables (hyperoxaluria and hypercalciuria,
respectively, defined each as a binary outcome variable),
multivariate logistic regression models were performed using a
stepwise backward procedure. The association between the
exposure variables and the presence of hyperoxaluria and
hypercalciuria, respectively, were expressed as Odds Ratio
(OR). In the final model p-values b0.05 were considered
significant.
3. Results
A total of 112 patients were included in the study. The main
clinical features of the population are reported in Table 1.
3.1. Glomerular filtration rate (GFR) according to the
estimated methods
Throughout the overall follow-up period, transiently de-
creased GFR(schw) (less than 90 ml/min/1.73 m2) was ob-
served in 21 patients (19%), mostly prior to the age of 3 years.
At the end of the study, no patient presented with a decreased
GFR(Schw) (median [IQR] 173 [150–197] ml/min/1.73 m2)
and there was no difference in GFR between children with
“severe” and “non-severe” mutations (p=0.18). GFR(schw)
values are reported in Fig. 1 according to the patients' age.
Data regarding GFR(uv/p) were only available for 24
patients. No correlation was found between GFR valuesobtained according to the Schwartz or UV/P formulae (n=41,
r=0.12, p=0.45). For 30% of the values, GFR was over-
estimated by the Schwartz formula, whereas UV/P values were
less than 90 ml/min/1.73 m2 (Fig. 2).
Although mean GFR(uv/p) was 105±43 ml/min/1.73 m2
(n=24), 14 patients had presented a GFR(uv/p) less than
90 ml/min/1.73 m2. Five of these patients showed regularly
Fig. 2. Correlation between GFR(schw) and GFR(uv/p). Results are in ml/min/
1.73 m2. n=41 values for 24 subjects (r=0.12, p=0.45). UV/P=[(urinary
creatinine×24-hour urinary volume) /plasma creatinine]× (1.73/body surface
area). Schwartz formula=[(k×height) / plasma creatinine]× (1.73/body surface
area). Horizontal line=UV/P value of 90 ml/min/1.73 m2. Vertical line=-
Schwartz value of 90 ml/min/1.73 m2.
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receiving regular intravenous antibiotic courses. This event
seemed to occur more likely after the age of 10–11 years.
However, there was no significant correlation between GFR
(schw) or GFR(uv/p) and the cumulative number of days of
aminoglycosides received by the patients (r=0.18, p=0.08 and
r=0.008, p=0.9, respectively) (Fig. 3). The results were similar
regarding all other antibiotics administered, including via the
inhaled route (data not shown). Noteworthy, a strong inverse
relationship between GFR(uv/p) and the cumulative dose of
netilmycin was observed in a very small number of patients
(n=4, r=−0.97, p=0.03) (data not shown).
3.2. Microalbuminuria
Increased albumin/creatinine ratio was observed in 22/38
(58%) patients. The mean age microalbuminuria was observedFig. 3. Correlation between GFR(schw) and the number of days of aminoglyco-
sides administered to all patients (n=105, r=0.18, p=0.08), including those
who had never received any antibiotics.was 8.4±4.8 years. The median values were 6.9 mg/mmol
(normal value b5 mg/mmol) and 2 mg/mmol (normal
valueb2 mg/mmol) in children under or above 2 years old,
respectively.3.3. Prevalence of urolithiasis and lithiasic risk factors
None of the patients presented with a symptomatic episode
of urolithiasis. However, urolithiasis was diagnosed by
ultrasonography in 2/109 (2%) patients.
One patient had numerous bilateral millimetric lithiasis
identified at the age of 3 months, with cristalluria analysis
revealing only isolated hypocitraturia. Another patient presented
with an asymptomatic non-obstructive pyelic urolithiasis
(main axis, 11 mm) at the age of 12 months. Cristalluria analysis
showed isolated hyperoxaluria. Regarding urolithiasic risk
factors, hyperoxaluria was observed in 58/83 (70%) patients,
hypocitraturia in 57/76 (75%) patients (median age at diagnosis
7.6 years and 9.7 years, respectively), hypercalciuria in 16/87
(18%), and hyperuricuria in 15/83 (18%) (Fig. 4). Sixteen per-
cent of patients had both hyperoxaluria and hypercalciuria.
Hypocitraturia was associated with hyperoxaluria and hypercal-
ciuria in 6/76 (8%) patients. Hyperoxaluria was associated with a
severe genotype (OR=2.15, 95% CI (1.75–20.35)), pancreatic
insufficiency (OR=2.16, 95% CI (1.74–20.99)) and liver disease
(OR=1.46, 95%CI (1.17–26.43)). Hypercalciuriawas associated
with liver disease (OR=2.59, 95% CI (1.01–11.01)). Values
of the oxalate/creatinine ratio are shown in Fig. 5, according to
the patient's age.4. Discussion
The present study, using the Schwartz formula, did not show
impaired GFR irrespective of the children's age group. More-
over, the correlation between Schwartz and UV/P GFR was
poor. The cumulative dose of aminoglycosides was not corre-
lated to GFR. Microalbuminuria was present in 58% of patients.
Hyperoxaluria was observed in 70% of patients and was asso-
ciated with a severe genotype, pancreas insufficiency and liverFig. 4. Prevalence of main lithiasic risk factors. Oxaluria (n=83), calciuria
(n=87), uricuria (n=83) and citraturia (n=76).
Fig. 5. Prevalence of hyperoxaluria according to age. Results are expressed in
median [IQR] of oxalate/creatinine ratio μmol/mmol, with extremities of the
boxes being minimal and maximal values. For 0.5–1 year old n=2, 1–3 years
n=18, 3–6 years n=29, 6–9 years n=24, 9–12 years n=25, 12–15 years n=21,
15–18 years n=5.
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identified in 75%, 18% and 18% of patients, respectively.
GFR impairment appears to be low in children with CF,
irrespective of nephrotoxic antibiotic administration. However,
the most widely-used method for GFR estimation, the Schwartz
formula, was initially assessed in a few healthy children only
[18] and may not be reliable for the early detection of impaired
GFR. Indeed, some authors have shown a 20% overestimated
GFR with this formula compared to inulin clearance, and only
an 80% sensitivity of this formula to screen for GFR less than
90 ml/min/1.73 m2 [21]. In paediatric allograft recipients, this
overestimation may attain 35% [22]. Reasons for erroneous
estimations of GFR by the Schwartz formula in children with
CF are numerous. First, the use of factor k in the numerator has
not been assessed in this specific population. A study in children
with chronic kidney disease that compared an optimized form of
the Schwartz equation with a measured iothalamate GFR
showed that the error of the GFR estimated by the Schwartz
formula approximated ±20 ml/min per 1.73 m² [23]. These
estimation errors may be substantially higher when creatinine
calibration differences from laboratory to laboratory are not
corrected. Second, the plasma creatinine level in the denomi-
nator may depend on diet, muscle mass, drug interaction and
laboratory problems such as colorimetric interferences. Also,
decline in hepatic function, observed in some patients with CF,
may result in decreased creatine production and lower plasma
creatinine levels.
The UV/P formula was another method used for the
estimation of GFR. In the present study it showed decreased
GFR in 14/24 patients, with a tendency to occur after the age of
12 years (9/14). This method has previously been applied in an
adult CF cohort by Al-Aloul et al., who showed that 42% of
patients had decreased GFR [9]. These results are compatible
with the hypothesis that renal impairment in CF is of
multifactorial origin, increasing over time and thus easier to
detect in older patients. Although some recent studies have
shown a strong correlation between measured creatinine
clearance and GFR calculated estimating formulae in adults
with CF [24], the different formulae for estimated GFR don't
seem to be reliable for accurate assessment of renal function inchildren with CF [25]. The early diagnosis of GFR impairment
in children with CF is thus difficult with the estimated method
commonly available. However, because of the numerous factors
that could affect renal function in the long term (dehydration,
infections, nephrotoxic drugs, diabetes, hyperoxaluria…), a
proper assessment is of capital importance. Thus, monitoring of
renal function should be performed using gold standard
methods such as inulin or Cr51 EDTA clearances, known to
be reliable and reproducible [21].
Microalbuminuria was observed in 58% of patients (22/38),
vs. 32% in a recent study including 40 adults with CF (without
diabetes mellitus) [26]. Primary impairment of the glomerular
filter is doubtable in CF since CFTR is not expressed in the
glomerule. However, secondary impairment may be explained
by chronic inflammation, repeated infections (glomerulone-
phritis caused by immune complex formation) [27], or
nephrotoxicity of antibiotics [9]. Unfortunately, the absence
of prospective collection of albuminuria in our study does not
allow concluding on the reliability of microalbuminuria as an
early sign of glomerular impairment in children with CF.
The prevalence of urolithiasis was lower in our study (2%)
compared to previous reported data including both adults and
children (3–6%) [28]. The early onset of lithiasis, within the
first year of life for both our patients, contrasts with previous
studies in which the first urolithiasic episode occurred in
adolescents or young adults, and in only one five-year old child
[28,29]. In the present study, one patient presented with
multiple bilateral microlithiases at the age of 3 months, with the
only risk factor identified being isolated hypocitraturia. A
similar case of nephrocalcinosis with isolated hypocitraturia has
previously been reported in a patient older than 15 years [5].
The prevalence of hyperoxaluria was greater than in former
studies including both children and adults with CF (70% vs. 40
to 65%) [5,7]. Noteworthy, only one patient presented with a
lithiasic complication. Hyperoxaluria may occur very early as
observed in the present study (two children prior to the age of
6 months, and 50% of patients between 1 and 3 years old).
This justifies the assessment of the oxalate/creatinine ratio as
soon as possible, once the diagnosis of CF is established. The
correlation between the occurrence of hyperoxaluria and the
presence of severe CFTR mutations and pancreatic insufficien-
cy may be explained by the fact that the severe mutations are
strongly associated with pancreatic insufficiency, which results
in malabsorptive hyperoxaluria. Indeed, digestive tract calcium
exhibits great affinity for excess fatty acids and its binding to
oxalate is thus disordered, allowing for enhanced soluble
oxalate intake [30]. Moreover, these mutations cause more
severe respiratory disease, with a greater need for IV antibiotics,
leading to the destruction of Oxalobacter formigenes within the
digestive tract. In a normal situation, this gram-negative bacillus
absorbs oxalate in order to produce ATP, thus contributing to
the limitation of oxalate intake. A lack of intestinal O.
formigenes would constitute an additional risk of absorptive
hyperoxaluria in patients with CF [7,31]. Thus, hyperoxaluria
should be considered an important lithiasic risk factor, with an
early onset and a high frequency among children with CF,
justifying early screening and appropriate management.
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was observed in 18% of patients. These results are similar to
those reported by other studies (12–20%) [5,29]. Hypercalciuria
may be explained by mild intermittent hyperparathyroidism due
to a lack of vitamin D [28] or to proximal tubule antibiotic
toxicity leading to renal loss of phosphorus [29]. Moreover,
increased sodium excretion (due to oral supplementation) in the
proximal tubule induces parallel urinary calcium excretion [32].
Hyperuricuria in our study was observed at a lower level than
in previous studies (18% vs. 25–55%) [5,6]. High protein diet
and purine-rich pancreatic enzyme supplements may represent
risk factors for enhanced urinary uric acid excretion in CF,
which promotes formation of oxalocalcic stones.
Hypocitraturia in CF may be linked to stool bicarbonate loss
leading tometabolic acidosis, which increases citrate reabsorption
by the proximal tubule. In the present study,we noted a higher rate
of hypocitraturia in patients compared to the literature (75% vs.
22–55%) [6,7]. Moreover, the observation of a 3-month-old
patient with multiple bilateral urolithiases and isolated hypoci-
traturia should encourage early screening and adequate treatment.
A low level of urinary creatinine may be expected in CF,
which would artificially increase creatinine dependent urinary
ratios. However, the high prevalence of hyperoxaluria and
hypercitraturia observed in the present study seems not to be
related to the use of oxalate/creatinine and citrate/creatinine
ratios. Indeed the prevalence of two other lithiasic risk factors
(hypercalciuria and hyperuricuria) also estimated using creat-
inine ratio is consistent with results from others studies using a
mmol/kg/day rate [5,29].
5. Conclusion
In summary, this study showed an increased risk of
oxalocalcic urolithiasis in children with CF. Irrespective of
nephrotoxic antibiotic administration, there appears to be low
levels of renal impairment. However, GFR may be under-
estimated, due to a lack of paraclinical tools specifically adapted
to this population. Further studies using optimal methods of
glomerular filtration rate measurements are thus warranted.
Screening for renal impairment, as early as in infancy, may be
appropriate, since early intervention will preserve optimal renal
function later in life.
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